IRIS Accounts Production v26.1.10.61 06267170 Board of Directors 1.12.24 30.11.25 30.11.25 false true false false true false iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh062671702024-11-30062671702025-11-30062671702024-12-012025-11-30062671702023-11-30062671702023-12-012024-11-30062671702024-11-3006267170ns14:PoundSterling2024-12-012025-11-3006267170ns10:Director12024-12-012025-11-3006267170ns10:PrivateLimitedCompanyLtd2024-12-012025-11-3006267170ns10:SmallEntities2024-12-012025-11-3006267170ns10:AuditExemptWithAccountantsReport2024-12-012025-11-3006267170ns10:SmallCompaniesRegimeForDirectorsReport2024-12-012025-11-3006267170ns10:SmallCompaniesRegimeForAccounts2024-12-012025-11-3006267170ns10:FullAccounts2024-12-012025-11-3006267170ns10:Director22024-12-012025-11-3006267170ns10:Director32024-12-012025-11-3006267170ns10:RegisteredOffice2024-12-012025-11-3006267170ns5:CurrentFinancialInstruments2025-11-3006267170ns5:CurrentFinancialInstruments2024-11-3006267170ns5:Non-currentFinancialInstruments2025-11-3006267170ns5:Non-currentFinancialInstruments2024-11-3006267170ns5:ShareCapital2025-11-3006267170ns5:ShareCapital2024-11-3006267170ns5:SharePremium2025-11-3006267170ns5:SharePremium2024-11-3006267170ns5:CapitalRedemptionReserve2025-11-3006267170ns5:CapitalRedemptionReserve2024-11-3006267170ns5:RetainedEarningsAccumulatedLosses2025-11-3006267170ns5:RetainedEarningsAccumulatedLosses2024-11-3006267170ns5:PlantMachinery2024-12-012025-11-3006267170ns5:FurnitureFittings2024-12-012025-11-3006267170ns5:PlantMachinery2024-11-3006267170ns5:FurnitureFittings2024-11-3006267170ns5:PlantMachinery2025-11-3006267170ns5:FurnitureFittings2025-11-3006267170ns5:PlantMachinery2024-11-3006267170ns5:FurnitureFittings2024-11-3006267170ns5:WithinOneYearns5:CurrentFinancialInstruments2025-11-3006267170ns5:WithinOneYearns5:CurrentFinancialInstruments2024-11-3006267170ns5:Non-currentFinancialInstrumentsns5:BetweenOneTwoYears2025-11-3006267170ns5:Non-currentFinancialInstrumentsns5:BetweenOneTwoYears2024-11-3006267170ns5:MoreThanFiveYearsns5:Non-currentFinancialInstruments2025-11-3006267170ns5:MoreThanFiveYearsns5:Non-currentFinancialInstruments2024-11-3006267170ns5:AcceleratedTaxDepreciationDeferredTax2025-11-3006267170ns5:AcceleratedTaxDepreciationDeferredTax2024-11-3006267170ns5:DeferredTaxation2024-11-3006267170ns5:DeferredTaxation2024-12-012025-11-3006267170ns5:DeferredTaxation2025-11-3006267170ns5:RetainedEarningsAccumulatedLosses2024-11-3006267170ns5:SharePremium2024-11-3006267170ns5:CapitalRedemptionReserve2024-11-3006267170ns5:RetainedEarningsAccumulatedLosses2024-12-012025-11-3006267170ns5:RetainedEarningsAccumulatedLosses2023-12-012024-11-30
REGISTERED NUMBER: 06267170















FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 NOVEMBER 2025

FOR

DENOVO HEALTHCARE LTD

DENOVO HEALTHCARE LTD (REGISTERED NUMBER: 06267170)






CONTENTS OF THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 NOVEMBER 2025




Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 4

Chartered Accountants' Report 8

DENOVO HEALTHCARE LTD

COMPANY INFORMATION
FOR THE YEAR ENDED 30 NOVEMBER 2025







DIRECTORS: Mr M A G Gibson
Mr N J Talbot
Mr R T G Gibson





REGISTERED OFFICE: 6A Wedmore Road
Cheddar
Somerset
BS27 3EB





REGISTERED NUMBER: 06267170





ACCOUNTANTS: Lowson Ward
Chartered Accountants
292 Wake Green Road
Birmingham
B13 9QP

DENOVO HEALTHCARE LTD (REGISTERED NUMBER: 06267170)

BALANCE SHEET
30 NOVEMBER 2025

30/11/25 30/11/24
Notes £    £   
FIXED ASSETS
Tangible assets 3 18,216 20,321

CURRENT ASSETS
Stocks 122,252 144,914
Debtors 4 463,897 454,300
Cash at bank 127,913 129,682
714,062 728,896
CREDITORS
Amounts falling due within one year 5 (485,317 ) (513,209 )
NET CURRENT ASSETS 228,745 215,687
TOTAL ASSETS LESS CURRENT
LIABILITIES

246,961

236,008

CREDITORS
Amounts falling due after more than
one year

6

(10,417

)

(35,417

)

PROVISIONS FOR LIABILITIES 7 (4,550 ) (5,080 )
NET ASSETS 231,994 195,511

DENOVO HEALTHCARE LTD (REGISTERED NUMBER: 06267170)

BALANCE SHEET - continued
30 NOVEMBER 2025

30/11/25 30/11/24
Notes £    £   
CAPITAL AND RESERVES
Called up share capital 60 60
Share premium 8 61,939 61,939
Capital redemption reserve 8 (138,460 ) (138,460 )
Retained earnings 8 308,455 271,972
SHAREHOLDERS' FUNDS 9 231,994 195,511

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 30 November 2025.

The members have not required the company to obtain an audit of its financial statements for the year ended 30 November 2025 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 12 August 2026 and were signed on its behalf by:





Mr N J Talbot - Director


DENOVO HEALTHCARE LTD (REGISTERED NUMBER: 06267170)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 NOVEMBER 2025

1. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Equipment - 33% on reducing balance
Premises improvements - straight line over lease term

All fixed assets are initially recorded at cost.

Stocks
Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Pension costs and other post-retirement benefits
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

DENOVO HEALTHCARE LTD (REGISTERED NUMBER: 06267170)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 30 NOVEMBER 2025

1. ACCOUNTING POLICIES - continued

Financial instruments
Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the entity after deducting all of its financial liabilities.

Where the contractual obligations of financial instruments (including share capital) are equivalent to a similar debt instrument, those financial instruments are classed as financial liabilities. Financial liabilities are presented as such in the balance sheet. Finance costs and gains or losses relating to financial liabilities are included in the profit and loss account. Finance costs are calculated so as to produce a constant rate of return on the outstanding liability.

Where the contractual terms of share capital do not have any terms meeting the definition of a financial liability then this is classed as an equity instrument. Dividends and distributions relating to equity instruments are debited direct to equity.

2. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 12 (2024 - 12 ) .

3. TANGIBLE FIXED ASSETS
Premises
Equipment improvements Totals
£    £    £   
COST
At 1 December 2024 86,978 50,280 137,258
Additions 4,351 1,180 5,531
At 30 November 2025 91,329 51,460 142,789
DEPRECIATION
At 1 December 2024 68,840 48,097 116,937
Charge for year 6,536 1,100 7,636
At 30 November 2025 75,376 49,197 124,573
NET BOOK VALUE
At 30 November 2025 15,953 2,263 18,216
At 30 November 2024 18,138 2,183 20,321

DENOVO HEALTHCARE LTD (REGISTERED NUMBER: 06267170)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 30 NOVEMBER 2025

4. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
30/11/25 30/11/24
£    £   
Trade debtors 389,834 384,303
Other debtors 60,000 60,000
Prepayments 14,063 9,997
463,897 454,300

5. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
30/11/25 30/11/24
£    £   
Trade creditors 318,163 370,628
Corporation tax 65,316 52,405
PAYE and NIC 8,591 5,182
VAT 73,570 71,142
Other creditors 7,430 4,191
Pension 1,051 1,013
Directors' current accounts 2,302 3,354
Accruals and deferred income 8,894 5,294
485,317 513,209

6. CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE YEAR
30/11/25 30/11/24
£    £   
Bank loans - 1-2 years 10,417 25,000
Other loans - 2-5 years - 10,417
10,417 35,417

7. PROVISIONS FOR LIABILITIES
30/11/25 30/11/24
£    £   
Deferred tax
Accelerated capital allowances 4,550 5,080

Deferred
tax
£   
Balance at 1 December 2024 5,080
Provided during year (530 )
Balance at 30 November 2025 4,550

DENOVO HEALTHCARE LTD (REGISTERED NUMBER: 06267170)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 30 NOVEMBER 2025

8. RESERVES
Capital
Retained Share redemption
earnings premium reserve Totals
£    £    £    £   

At 1 December 2024 271,972 61,939 (138,460 ) 195,451
Profit for the year 221,841 - - 221,841
Dividends (185,358 ) - - (185,358 )
At 30 November 2025 308,455 61,939 (138,460 ) 231,934

9. RECONCILIATION OF MOVEMENTS IN SHAREHOLDERS' FUNDS
30/11/25 30/11/24
£    £   
Profit for the financial year 221,841 193,518
Dividends (185,358 ) (178,000 )
36,483 15,518
Opening shareholders' funds - 179,993
Net addition to shareholders' funds 36,483 195,511
Opening shareholders' funds 195,511 -
Closing shareholders' funds 231,994 195,511

CHARTERED ACCOUNTANTS' REPORT TO THE BOARD OF DIRECTORS
ON THE UNAUDITED FINANCIAL STATEMENTS OF
DENOVO HEALTHCARE LTD

The following reproduces the text of the report prepared for the directors in respect of the company's annual unaudited financial statements. In accordance with the Companies Act 2006, the company is only required to file a Balance Sheet. Readers are cautioned that the Income Statement and certain other primary statements and the Report of the Directors are not required to be filed with the Registrar of Companies.

In order to assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the financial statements of Denovo Healthcare Ltd for the year ended 30 November 2025 which comprise the Income Statement, Balance Sheet and the related notes from the company's accounting records and from information and explanations you have given us.

As a practising member firm of the Institute of Chartered Accountants in England and Wales (ICAEW), we are subject to its ethical and other professional requirements which are detailed within the ICAEW's regulations and guidance at http://www.icaew.com/en/membership/regulations-standards-and-guidance.

This report is made solely to the Board of Directors of Denovo Healthcare Ltd, as a body, in accordance with our terms of engagement. Our work has been undertaken solely to prepare for your approval the financial statements of Denovo Healthcare Ltd and state those matters that we have agreed to state to the Board of Directors of Denovo Healthcare Ltd, as a body, in this report in accordance with ICAEW Technical Release 07/16AAF. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than Denovo Healthcare Ltd and its Board of Directors, as a body, for our work or for this report.

It is your duty to ensure that Denovo Healthcare Ltd has kept adequate accounting records and to prepare statutory financial statements that give a true and fair view of the assets, liabilities, financial position and profit of Denovo Healthcare Ltd. You consider that Denovo Healthcare Ltd is exempt from the statutory audit requirement for the year.

We have not been instructed to carry out an audit or a review of the financial statements of Denovo Healthcare Ltd. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the statutory financial statements.






Lowson Ward
Chartered Accountants
292 Wake Green Road
Birmingham
B13 9QP


12 August 2026